Copeptin is independently associated with vascular calcification in chronic kidney disease stage 5

Abstract Background Vascular calcification (VC) is an independent predictor of cardiovascular disease (CVD) present in 30–70% of patients with chronic kidney disease (CKD). Copeptin is a sensitive surrogate marker of arginine vasopressin (AVP), which is involved in many pathophysiologic processes in...

Full description

Bibliographic Details
Main Authors: Edyta Golembiewska, Abdul Rashid Qureshi, Lu Dai, Bengt Lindholm, Olof Heimbürger, Magnus Söderberg, Torkel B. Brismar, Jonaz Ripsweden, Peter Barany, Richard J. Johnson, Peter Stenvinkel
Format: Article
Language:English
Published: BMC 2020-02-01
Series:BMC Nephrology
Subjects:
Online Access:https://doi.org/10.1186/s12882-020-1710-6
id doaj-983b6db0075d442eb7875c35dfc7d564
record_format Article
spelling doaj-983b6db0075d442eb7875c35dfc7d5642021-02-07T12:49:05ZengBMCBMC Nephrology1471-23692020-02-012111810.1186/s12882-020-1710-6Copeptin is independently associated with vascular calcification in chronic kidney disease stage 5Edyta Golembiewska0Abdul Rashid Qureshi1Lu Dai2Bengt Lindholm3Olof Heimbürger4Magnus Söderberg5Torkel B. Brismar6Jonaz Ripsweden7Peter Barany8Richard J. Johnson9Peter Stenvinkel10Division of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Campus FlemingsbergDivision of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Campus FlemingsbergDivision of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Campus FlemingsbergDivision of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Campus FlemingsbergDivision of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Campus FlemingsbergCardiovascular, Renal and Metabolism Safety, Clinical Pharmacology & Safety Sciences R&D, AstraZenecaDivision of Medical Imaging and Technology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Campus FlemingsbergDivision of Medical Imaging and Technology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Campus FlemingsbergDivision of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Campus FlemingsbergDivision of Renal Diseases and Hypertension, School of Medicine, University of ColoradoDivision of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Campus FlemingsbergAbstract Background Vascular calcification (VC) is an independent predictor of cardiovascular disease (CVD) present in 30–70% of patients with chronic kidney disease (CKD). Copeptin is a sensitive surrogate marker of arginine vasopressin (AVP), which is involved in many pathophysiologic processes in CKD. The aim of the present study was to explore the association of copeptin with VC in CKD stage 5. Methods Copeptin was investigated in conjunction with living donor kidney transplantation in 149 clinically stable CKD stage 5 patients (CKD5), including 53 non-dialyzed (CKD5-ND) and 96 dialysis patients treated by peritoneal dialysis (PD) (n = 43) or hemodialysis (HD) (n = 53). We analyzed the association of copeptin with presence and extent of VC ascertained both histologically in biopsies from the inferior epigastric artery (n = 137) and by coronary artery calcification (CAC) score measured by computed tomography. Results Patients with higher copeptin were older, had higher systolic blood pressure, higher prevalence of CVD and their preceding time on chronic dialysis was longer. In Spearman’s rank correlations (Rho), copeptin concentrations were significantly associated with CAC score (Rho = 0.27; p = 0.003) and presence of medial VC (Rho = 0.21; p = 0.016). Multivariate logistic regression analysis showed that 1-SD higher age, male gender, diabetes and 1-SD higher copeptin were significantly associated with the presence of moderate-extensive VC. Conclusions High circulating levels of copeptin in CKD5 patients are independently associated with the degree of medial calcification ascertained by histology of arterial biopsies. Thus, plasma copeptin may serve as a marker of the uremic calcification process.https://doi.org/10.1186/s12882-020-1710-6CopeptinChronic kidney diseaseEnd-stage renal diseaseVascular calcification
collection DOAJ
language English
format Article
sources DOAJ
author Edyta Golembiewska
Abdul Rashid Qureshi
Lu Dai
Bengt Lindholm
Olof Heimbürger
Magnus Söderberg
Torkel B. Brismar
Jonaz Ripsweden
Peter Barany
Richard J. Johnson
Peter Stenvinkel
spellingShingle Edyta Golembiewska
Abdul Rashid Qureshi
Lu Dai
Bengt Lindholm
Olof Heimbürger
Magnus Söderberg
Torkel B. Brismar
Jonaz Ripsweden
Peter Barany
Richard J. Johnson
Peter Stenvinkel
Copeptin is independently associated with vascular calcification in chronic kidney disease stage 5
BMC Nephrology
Copeptin
Chronic kidney disease
End-stage renal disease
Vascular calcification
author_facet Edyta Golembiewska
Abdul Rashid Qureshi
Lu Dai
Bengt Lindholm
Olof Heimbürger
Magnus Söderberg
Torkel B. Brismar
Jonaz Ripsweden
Peter Barany
Richard J. Johnson
Peter Stenvinkel
author_sort Edyta Golembiewska
title Copeptin is independently associated with vascular calcification in chronic kidney disease stage 5
title_short Copeptin is independently associated with vascular calcification in chronic kidney disease stage 5
title_full Copeptin is independently associated with vascular calcification in chronic kidney disease stage 5
title_fullStr Copeptin is independently associated with vascular calcification in chronic kidney disease stage 5
title_full_unstemmed Copeptin is independently associated with vascular calcification in chronic kidney disease stage 5
title_sort copeptin is independently associated with vascular calcification in chronic kidney disease stage 5
publisher BMC
series BMC Nephrology
issn 1471-2369
publishDate 2020-02-01
description Abstract Background Vascular calcification (VC) is an independent predictor of cardiovascular disease (CVD) present in 30–70% of patients with chronic kidney disease (CKD). Copeptin is a sensitive surrogate marker of arginine vasopressin (AVP), which is involved in many pathophysiologic processes in CKD. The aim of the present study was to explore the association of copeptin with VC in CKD stage 5. Methods Copeptin was investigated in conjunction with living donor kidney transplantation in 149 clinically stable CKD stage 5 patients (CKD5), including 53 non-dialyzed (CKD5-ND) and 96 dialysis patients treated by peritoneal dialysis (PD) (n = 43) or hemodialysis (HD) (n = 53). We analyzed the association of copeptin with presence and extent of VC ascertained both histologically in biopsies from the inferior epigastric artery (n = 137) and by coronary artery calcification (CAC) score measured by computed tomography. Results Patients with higher copeptin were older, had higher systolic blood pressure, higher prevalence of CVD and their preceding time on chronic dialysis was longer. In Spearman’s rank correlations (Rho), copeptin concentrations were significantly associated with CAC score (Rho = 0.27; p = 0.003) and presence of medial VC (Rho = 0.21; p = 0.016). Multivariate logistic regression analysis showed that 1-SD higher age, male gender, diabetes and 1-SD higher copeptin were significantly associated with the presence of moderate-extensive VC. Conclusions High circulating levels of copeptin in CKD5 patients are independently associated with the degree of medial calcification ascertained by histology of arterial biopsies. Thus, plasma copeptin may serve as a marker of the uremic calcification process.
topic Copeptin
Chronic kidney disease
End-stage renal disease
Vascular calcification
url https://doi.org/10.1186/s12882-020-1710-6
work_keys_str_mv AT edytagolembiewska copeptinisindependentlyassociatedwithvascularcalcificationinchronickidneydiseasestage5
AT abdulrashidqureshi copeptinisindependentlyassociatedwithvascularcalcificationinchronickidneydiseasestage5
AT ludai copeptinisindependentlyassociatedwithvascularcalcificationinchronickidneydiseasestage5
AT bengtlindholm copeptinisindependentlyassociatedwithvascularcalcificationinchronickidneydiseasestage5
AT olofheimburger copeptinisindependentlyassociatedwithvascularcalcificationinchronickidneydiseasestage5
AT magnussoderberg copeptinisindependentlyassociatedwithvascularcalcificationinchronickidneydiseasestage5
AT torkelbbrismar copeptinisindependentlyassociatedwithvascularcalcificationinchronickidneydiseasestage5
AT jonazripsweden copeptinisindependentlyassociatedwithvascularcalcificationinchronickidneydiseasestage5
AT peterbarany copeptinisindependentlyassociatedwithvascularcalcificationinchronickidneydiseasestage5
AT richardjjohnson copeptinisindependentlyassociatedwithvascularcalcificationinchronickidneydiseasestage5
AT peterstenvinkel copeptinisindependentlyassociatedwithvascularcalcificationinchronickidneydiseasestage5
_version_ 1724280655833989120